Editas Medicine Inc
EDIT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$324.48M
Close$
$-1.25
145.8% downside
Current Fair Value
145.8% downsideOvervalued by 145.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $324.48 Million |
|---|---|
| Enterprise Value | $190.49 Million |
| Earnings per Share | $-1.8 |
| Beta | 2 |
| Outstanding Shares | 119,294,615 |
Return
| Return on Equity | -70.24% |
|---|---|
| Return on Assets | -31.15% |
| Return on Invested Capital | 62.24% |
Valuation & Multiples
| P/E Ratio | -3.57 |
|---|---|
| PEG | 5.43 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.31 |
| Enterprise Value to EBIT | 1.81 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 0.45 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.27
Consensus analyst estimateRevenue Estimate
$2.85 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.21
Consensus analyst estimateRevenue Estimate
$4.53 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 36.42% |
|---|---|
| Total Calls | 10,000▼ 99.12% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.34%▼ 100.39% |
|---|---|
| Total Invested | $1.11M▼ 99.71% |
| Investors Holding | 52▼ 173.00% |
About Editas Medicine Inc
87 employees
CEO: Cynthia Collins
Editas Medicine, Inc. is a clinical-stage company dedicated to developing innovative genomic medicines that address a range of serious diseases. The company utilizes its proprietary gene editing platform, which is founded on CRISPR techn...